Escherichia coli Nissle 1917 enhances bioavailability of serotonin in gut tissues through modulation of synthesis and clearance

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Nzakizwanayo, Jonathan ^a   Dedi, Cinzia ^a   Standen, Guy ^a   Macfarlane, Wendy M ^a   Patel, Bhavik A ^a   Jones, Brian V ^a,b  

^a UNIVERSITY OF BRIGHTON   (United Kingdom)

^b QUEEN VICTORIA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; SEROTONIN;

ANIMAL; BIOAVAILABILITY; BIOLOGICAL MODEL; ESCHERICHIA COLI; EXTRACELLULAR SPACE; GASTROINTESTINAL TRACT; MALE; METABOLISM; MICROBIOLOGY; MOUSE; PHYSIOLOGY; SYNAPTIC TRANSMISSION;

ANIMALS; BIOLOGICAL AVAILABILITY; ESCHERICHIA COLI; EXTRACELLULAR SPACE; FATTY ACIDS; GASTROINTESTINAL TRACT; MALE; MICE; MODELS, BIOLOGICAL; SEROTONIN; SYNAPTIC TRANSMISSION;

EID: 84948671061     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep17324     Document Type: Article

References (75)

1. Ley, R. E., Peterson, D. A. and Gordon, J. I. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 124, 837-848 (2006).
2. OHara, A. M. and Shanahan, F. The gut flora as a forgotten organ. EMBO Rep. 7, 688-693 (2006).
3. Wilks, M. Bacteria and early human development. Early Hum. Dev. 83, 165-170 (2007).
4. Qin, J. et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464, 59-65 (2010).
5. Ogilvie, L. A., Ferouzimand, S. and Jones, B. V. Evolutionary, Ecological, and Biotechnological perspectives on plasmids resident in the human gut mobile metagenome, Bioeng Bugs 1, 1-19 (2012).
6. FAO/WHO. Guidelines for the evaluation of probiotics in food. Report of a Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food; Ontario, Canada. April 30, May 1, 2002.
7. Foxx-Orenstein, A. and Chey, W. D. Manipulation of the gut microbiota as a novel treatment strategy for gastrointestinal disorders. Am. J. Gastroenterol. Suppl. 1, 41-46 (2012).
8. Shanahan, F. Therapeutic implications of manipulating and mining the microbiota. J. Physiol. 587, 4175-4179 (2009).
9. OSullivan, G. C et al. Probiotics: an emerging therapy. Curr. Pharm. Des. 11, 3-10 (2005).
10. Ringel, Y., Quigley, E. M. M. and Li, H.C. Using probiotics in gastrointestinal disorders. Am. J. Gastroenterol. 1, 34-40.
11. Sonnenborn, U. and Schulze, J. The non-pathogenic Escherichia coli strain Nissle 1917-features of a versatile probiotic. Microb. Ecol. Health Dis. 21, 122-158 (2009).
12. Kopp-Hoolihan, L. Prophylactic and therapeutic uses of probiotics: a review. J Am Diet Assoc 101, 229-238 (2001).
13. Clarke, G. et al. The microbiome-gut-brain axis during early life regulates the hippocampal serotonergic system in a sexdependent manner. Mol. Psychiatry 18, 666-673 (2013).
14. Nissle, A. Die antagonistische Behandlung chronischer Darmstorungen mit Colibakterien. Med Klin. 2, 29-33 (1918).
15. Kruis, W. et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment. Pharmacol. Ther. 11, 853-858 (1997).
16. Kruis, W. et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53, 1617-1623 (2004).
17. Schultz, M. Clinical use of E. coli Nissle 1917 in inflammatory bowel disease. Inflamm. Bowel Dis. 14, 1012-1018 (2008).
18. Matthes, H., Krummenerl, T., Giensch, M., Wolff, C. and Schulze, J. Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). BMC Complement Altern Med 10, 13 (2010). doi: 10.1186/1472-6882-10-13.
19. Cukrowska, B. et al. Specific proliferative and antibody responses of premature infants to intestinal colonization with nonpathogenic probiotic E. coli strain Nissle 1917. Scand. J. Immunol. 55, 204-209 (2002).
20. Henker, J. et al. The probiotic Escherichia coli strain Nissle 1917 (EcN) stops acute diarrhoea in infants and toddlers. Eur. J. Pediatr. 166, 311-318 (2007).
21. Boudeau, J., Glasser, A. L., Julien, S., Colombel, J. F. and Darfeuille-Michaud, A.Inhibitory effect of probiotic Escherichia coli strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent-invasive E. coli strains isolated from patients with Crohns disease. Aliment. Pharmacol. Ther. 18, 45-56 (2003).
22. Mollenbrink, M. and Bruckschen, E. Treatment of chronic constipation with physiologic Escherichia coli bacteria. Results of a clinical study of the effectiveness and tolerance of microbiological therapy with the E. coli Nissle 1917 strain (Mutaflor). Med. Klin. (Munich) 89, 587-593 (1994).
23. Kruis, W., Chrubasik, S., Boehm, S., Stange, C. and Schulze, J. A double-blind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome. Int J Colorectal Dis. 27, 467-474 (2012).
24. Kim, D. Y. and Camilleri, M. Serotonin: a mediator of the brain-gut connection. Am. J. Gastroenterol. 95, 2698-2709 (2000).
25. Gershon, M. D. and Tack, J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 132, 397-414 (2007).
26. Fuller, R. W. and Wong, D. T. Serotonin uptake and serotonin uptake inhibition. Ann. N. Y. Acad. Sci. 600, 68-78 (1990).
27. Sjolund, K, Sanden, G., Hakanson, R. and Sundler, F. Endocrine cells in human intestine: an immunocytochemical study. Gastroenterology 85, 1120-1230 (1983).
28. Gershon, M. D. Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment. Pharmacol. Ther. 13, 15-30 (1999).
29. Plockinger, U. Neuroendocrine tumors. In Gastrointestinal Oncology: A Critical Multidisciplinary Team Approach (eds Jankowski, J., Sampliner, R., Kerr, D. and Fong, Y.) Ch 23, pp. 565 (Blackwell Publishing, Oxfod, UK, 2008).
30. Baganz, N. L. and Blakely, R. D. A dialogue between the immune system and brain, spoken in the language of serotonin. ACS Chem Neurosci 4, 48-63 (2013).
31. Cote, F. et al. Disruption of the nonneuronal tph1 gene demonstrates the importance of peripheral serotonin in cardiac function. Proc. Natl. Acad. Sci. USA 100, 13525-15330 (2003).
32. Chabbi-Achengli, Y. et al. Decreased osteoclastogenesis in serotonin-deficient mice. Proc. Natl. Acad. Sci. USA 109, 2567-2572 (2012).
33. Yadav, V. K. et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 35, 825-837 (2008).
34. Leonard, B. E. HPA and immune axes in stress: involvement of the serotonergic system. Neuroimmunomodulation 13, 268-276 (2006).
35. Linden, D. R., Chen, J. X., Gershon, M. D, Sharkey, K. A. and Mawe, G. M. Serotonin availability is increased in mucosa of guinea pigs with TNBS-induced colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 285, G207-216 (2003).
36. Coates, M. D. et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 126, 1657-1664 (2004).
37. Manocha, M. and Khan, W. I. Serotonin and GI Disorders: An Update on Clinical and Experimental Studies. Clin Transl Gastroenterol 3, e13 (2012). doi: 10.1038/ctg.2012.8.
38. Stasi, C., Bellini, M., Bassotti, G., Blandizzi, C. and Milani, S. Serotonin receptors and their role in the pathophysiology and therapy of irritable bowel syndrome. Tech Coloproctol 18, 613-621 (2014).
39. Costedio, M. M., Hyman, N. and Mawe, G. M. Serotonin and its role in colonic function and in gastrointestinal disorders. Dis. Colon Rectum 50, 376-388 (2007).
40. Diss, L. B. et al. Age-related changes in melatonin release in the murine distal colon. ACS Chem Neurosci 4, 879-887 (2013).
41. Patel, B. A. et al. Impaired colonic motility and reduction in tachykinin signalling in the aged mouse. Exp. Gerontol. 53, 24-30 (2014).
42. Heijtz, R. D. et al. Normal gut microbiota modulates brain development and behavior. Proc. Natl. Acad. Sci. USA 108, 3047-3052 (2011).
43. Yano, J. M. et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell 161, 264-276 (2015).
44. Wikoff, W. R. et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc. Natl. Acad. Sci. USA 106, 3698-3703 (2009).
45. Hafez, M. et al. The K5 capsule of Escherichia coli strain Nissle 1917 is important in mediating interactions with intestinal epithelial cells and chemokine induction. Infect. Immun. 77, 2995-3003 (2009).
46. Nzakizwanayo, J. et al. Disruption of Escherichia coli Nissle 1917 K5 capsule biosynthesis, through loss of distinct kfi genes, modulates interaction with intestinal epithelial cells and impact on cell health. PLoS ONE 10, e0120430. doi: 10.1371/journal. pone.0120430.
47. Fukumoto, S. et al. Short-chain fatty acids stimulate colonic transit via intraluminal 5-HT release in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284, R1269-1276 (2003).
48. Cryan, J. F. and OMahony, S. M. The microbiome-gut-brain axis: from bowel to behavior. Neurogastroenterol. Motil. 23, 187-192 (2011).
49. Camilleri, M. Treating irritable bowel syndrome: overview, perspective and future therapies. Br. J. Pharmacol.141, 1237-1248 (2004).
50. Mayer, E. A. and Bradesi, S. Alosetron and irritable bowel syndrome. Expert Opin Pharmacother 4, 2089-2098 (2003).
51. Wehkamp, J. et al. NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect. Immun. 72, 5750-5758 (2004).
52. Schlee, M. et al. Induction of human beta-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin. Infect. Immun. 75, 2399-2407 (2007).
53. Hering, N. A. et al. TcpC protein from E. coli Nissle improves epithelial barrier function involving PKC and ERK1/2 signaling in HT-29/B6 cells.Mucosal Immunol 7, 369-378 (2014).
54. Bar, F. et al. Cell-free supernatants of Escherichia coli Nissle 1917 modulate human colonic motility: evidence from an in vitro organ bath study. Neurogastroenterol. Motil. 21, 559-566 (2009).
55. Sturm, A. et al. Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signaling. Infect. Immun. 73, 1452-1465 (2005).
56. Helwig, U. et al. Lactobacilli, bifidobacteria and E. coli nissle induce pro- and anti-inflammatory cytokines in peripheral blood mononuclear cells. World J. Gastroenterol. 12, 5978-5986 (2006).
57. Jones, B. V., Begley, M., Hill, C., Gahan, C. G. and Marchesi, J. R. Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome. Proc. Natl. Acad. Sci. USA 105, 13580-13585 (2008).
58. Ogilvie, L. A. and Jones, B. V. Dysbiosis modulates capacity for bile acid modification in the gut microbiomes of patients with inflammatory bowel disease: a mechanism and marker of disease? Gut 61, 1642-1643 (2012).
59. Ridlon, J. M., Kang, D.-Y. and Hylemon P. B. Biotransformations by human intestinal bacteria. J. Lipid Res. 47, 241-259 (2006).
60. Valentin, H. E. and Qi, Q. Biotechnological production and application of vitamin E: current state and prospects. Appl. Microbiol. Biotechnol. 68, 436-444 (2005).
61. de Crecy-Lagard, V., El Yacoubi, B., de la Garza, R. D., Noiriel, A. and Hanson, A. D. Comparative genomics of bacterial and plant folate synthesis and salvage: predictions and validations. BMC Genomics 8, 245 (2007).
62. Williams, B. B. et al. Discovery and characterization of gut microbiota decarboxylases that can produce the neurotransmitter tryptamine. Cell Host Microbe 16, 495-503 (2014).
63. Marcobal, A., De las Rivas, B., Landete, J. M., Tabera, L. and Munoz, R. Tyramine and phenylethylamine biosynthesis by food bacteria. Crit Rev Food Sci Nutr 52, 448-467 (2012).
64. Rossi, M., Amaretti, A. and Raimondi, S. Folate production by probiotic bacteria. Nutrients 3, 118-134 (2011).
65. Diksic, M. and Young, S. N.Study of the brain serotonergic system with labeled alpha-methyl-L-tryptophan. J. Neurochem. 78, 1185-1200 (2001).
66. Walther, D. J. and Bader, M. A unique central tryptophan hydroxylase isoform. Biochem. Pharmacol. 66, 1673-1680 (2003).
67. Walther, D. J. et al. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 299, 76 (2003).
68. Crowell, M. D. Role of serotonin in the pathophysiology of irritable bowel syndrome. British Journal of Pharmacology 141(8), 1285-1293 (2004).
69. Khan, W. I. The role of 5-HT dysregulation in inflammatory bowel disease. Gastroenterology and Hepaology 9, 259-261 (2013).
70. Blattner, F. R. et al. The complete genome sequence of Escherichia coli K-12. Science 277, 1453-1474 (1997).
71. Lwin, A. and Patel, B. A. High performance liquid chromatography method for the detection of released purinergic and biogenic amine signaling molecules from in vitro ileum tissue. J Sep Sci 33, 1538-1545 (2010).
72. Parmar, L., Morgan, L. D. and Patel, B. A. Intracellular and extracellular sampling to monitor the neurotransmission process using a chromatographic method. Anal Meth. 3, 2770-2776 (2011).
73. Patel, B. A. Electroanalytical approaches to study signaling mechanisms in the gastrointestinal tract. Neurogastroenterol. Motil. 23, 595-605 (2011).
74. Patel, B. A., Bian, X., Quaiserova-Mocko, V., Galligan, J. J. and Swain, G. M. In vitro continuous amperometric monitoring of 5-hydroxytryptamine release from enterochromaffin cells of the guinea pig ileum. Analyst 132, 41-47 (2007).
75. Schiffels, J., Baumann, M. E. and Selmer, T. Facile analysis of short-chain fatty acids as 4-nitrophenyl esters in complex anaerobic fermentation samples by high performance liquid chromatography. J Chromatogr A 1218, 5848-5851 (2011).